Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Haemonetics (HAE) Stock Price & Analysis
347 Followers
HAE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$70.74 - $97.97
Previous Close$88.73
Volume326.96K
Average Volume (3M)593.13K
Market Cap
$4.52B
Enterprise Value$5.15B
Total Cash (Recent Filing)$178.80M
Total Debt (Recent Filing)$807.79M
Price to Earnings (P/E)38.8
Beta0.86
Next Earnings
Aug 08, 2024EPS Estimate
$1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.29
Shares Outstanding50,841,442
10 Day Avg. Volume520,617
30 Day Avg. Volume593,125
Standard Deviation0.12
R-Squared0.03
Alpha0.00014
Financial Highlights & Ratios
Price to Book (P/B)-385.34
Price to Sales (P/S)12.62
Price to Cash Flow (P/CF)16.90
P/FCF Ratio18.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.93
Enterprise Value/Gross Profit7.45
Enterprise Value/Ebitda20.17
Forecast
1Y Price Target
$114.75Price Target Upside29.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Haemonetics News
Bulls Say, Bears Say
Bulls Say
EarningsHAE delivered another upside quarter on the top and bottom lines and issued initial FY25 guidance that calls for sales growth of 5-8%.
Hospital Unit GrowthThe hospital unit grew 28.1% on a reported basis and was up 18.7% on an organic basis.
Product InnovationHAE's new products offer significant value in the plasma collection industry, with the ability to increase donor yield and save time.
Bears Say
EarningsHAE sees $85mn of sales in FY25 from CSL, down from $155mn in FY24.
GrowthPlasma growth slowed to 6% organic in F4Q24 from 8% organic in F3Q24.
RevenueRevenue associated with the anticipated winddown in the CSL relationship could provide somewhat of a headwind versus last year’s comparable period.
---
Ownership Overview
2.73% Insiders
49.66% Mutual Funds
26.21% Other Institutional Investors
21.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $70.74 and its highest was $97.97 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Currently, no data Available
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on May 09, 2024. The company reported $0.9 earnings per share for the quarter, beating the consensus estimate of $0.892 by $0.008.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is $1.01.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 50,953,100 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $0.9 in its last earnings report, beating expectations of $0.892. Following the earnings report the stock price went down -0.697%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Among the largest hedge funds holding Haemonetics Corp.’s share is Royce & Associates LLC. It holds Haemonetics Corp.’s shares valued at 108M.
---
Haemonetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.75 (29.32% Upside)
$114.75 (29.32% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 265.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 16.5%
Last 30 Days ▲ 16.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.54%
12-Months-Change
Fundamentals
Return on Equity
13.22%
Trailing 12-Months
Asset Growth
13.48%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
---
HAE Earnings Call
Q4 2024
0:00 / 0:00
---
HAE Stock 12 Month Forecast
Average Price Target
$114.75
▲(29.32% Upside)
Technical Analysis
Best Analysts Covering HAE
1 Year
1 Year Success Rate
25/39 ratings generated profit
1 Year Average Return
+12.96%
reiterated a buy rating 2 months ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 64.10% of your transactions generating a profit, with an average return of +12.96% per trade.
---